Supplementary Table 1. T-cell phenotype and numbers before and after NACT in primary tumor samples from patients with cervical cancer.

| Target population | Phenotype | Area          | Cisplatin (n=6) | Cisplatin + paclitaxel (n=7) |
|-------------------|-----------|---------------|-----------------|-----------------------------|
|                   |           |               | Pre-NACT        | Post-NACT                   | Pre-NACT        | Post-NACT                   |
| T cells           | CD3⁺      | Stromal       | 2365.2 ± 697.8 | 2969.5 ± 895.3             | 3833.3 ± 694.3 | 5189.6 ± 876.2             |
|                   |           | Intratumoral  | 1092.7 ± 141.7 | 1892.1 ± 501.1             | 1308.0 ± 315.6 | 1310.8 ± 223.4             |
| CD8⁺ T cells      | CD3⁺CD8⁺  | Stromal       | 1673.5 ± 657.7 | 2102.2 ± 765.5             | 2660.8 ± 505.4 | 2388.5 ± 568.6             |
|                   |           | Intratumoral  | 612.4 ± 66.6   | 1111.3 ± 375.8             | 795.7 ± 236.5  | 721.9 ± 159.3              |
| CD8⁺ T cells      | CD3⁺CD8⁺  | Stromal       | 192.6 ± 38.0   | 449.6 ± 119.8              | 509.0 ± 134.5  | 2166.3 ± 544.1*            |
|                   |           | Intratumoral  | 358.3 ± 173.8  | 526.3 ± 193.1              | 330.0 ± 81.6   | 453.6 ± 145.6              |
| Tregs             | CD3⁺CD8⁺FoxP3⁺ | Stromal     | 461.3 ± 173.1  | 238.3 ± 58.0               | 566.5 ± 108.4  | 488.2 ± 198.0              |
|                   |           | Intratumoral  | 105.7 ± 24.7   | 166.1 ± 74.0               | 123.0 ± 65.4   | 123.0 ± 65.4               |
| CD8⁺ T cell/Treg  |          | Stromal       | 1.0 ± 0.6      | 1.2 ± 0.2                  | 1.2 ± 0.4      | 16.8 ± 8.4                 |
|                   |          | Intratumoral  | 4.8 ± 2.7      | 3.5 ± 1.5                  | 8.4 ± 4.3      | 29.3 ± 24.7                |
| FoxP3⁺CD8⁺ T cells| CD3⁺CD8⁺FoxP3⁺ | Stromal     | 37.7 ± 27.3    | 56.2 ± 24.9                | 41.9 ± 16.2    | 177.2 ± 55.1*              |
|                   |           | Intratumoral  | 16.3 ± 11.6    | 16.3 ± 7.9                 | 16.3 ± 7.5     | 12.3 ± 4.1                 |
| Proliferating CD8⁺ T cells | CD3⁺CD8⁺Ki67⁺ | Stromal     | 360.4 ± 144.3  | 239.8 ± 121.9              | 624.2 ± 131.2  | 240.2 ± 95.5*              |
|                   |           | Intratumoral  | 302.9 ± 67.8   | 464.1 ± 233.4              | 403.7 ± 99.4   | 107.7 ± 28.4               |
| Proliferating CD8⁺ T cells | CD3⁺CD8⁺Ki67⁺ | Stromal     | 106.0 ± 57.8   | 85.5 ± 37.4                | 143.2 ± 36.7   | 168.7 ± 53.0               |
|                   |           | Intratumoral  | 299.1 ± 171.3  | 261.7 ± 138.4              | 252.9 ± 67.2   | 60.4 ± 23.1                |
| Proliferating cells | Ki67⁺(CD3 CD8⁺) | Stromal     | 1065.8 ± 241.8 | 599.1 ± 252.7              | 2201.6 ± 446.8 | 451.3 ± 199.2*             |
|                   |           | Intratumoral  | 4534.0 ± 1159.0 | 4456.5 ± 959.5        | 7052.2 ± 996.6 | 1795.3 ± 1168.9            |
| Proliferating Tregs | CD8⁺FoxP3⁺Ki67⁺ | Stromal     | 90.7 ± 29.7    | 51.7 ± 13.3                | 184.7 ± 39.3   | 83.6 ± 35.0*               |
|                   |           | Intratumoral  | 52.5 ± 12.2    | 100.7 ± 26.2               | 83.9 ± 33.8    | 34.1 ± 15.2                |
| Proliferating FoxP3⁺CD8⁺ T cells | CD8⁺FoxP3⁺Ki67⁺ | Stromal     | 23.0 ± 21.5    | 8.5 ± 4.1                  | 13.6 ± 6.3     | 31.2 ± 10.1                |
|                   |           | Intratumoral  | 3.2 ± 1.5      | 7.6 ± 4.0                  | 10.1 ± 4.5     | 2.1 ± 0.7                  |
| Tbet⁺CD8⁺ T cells | CD3⁺CD8⁺Tbet⁺ | Stromal     | 549.7 ± 136.4  | 606.5 ± 131.5              | 1072.2 ± 272.6 | 583.7 ± 113.4             |
|                   |           | Intratumoral  | 205.4 ± 47.5   | 333.5 ± 76.5               | 278.6 ± 92.1   | 178.1 ± 48.1               |
| Tbet⁺CD8⁺ T cells | CD3⁺CD8⁺Tbet⁺ | Stromal     | 124.6 ± 33.7   | 231.9 ± 62.3               | 297.1 ± 98.9   | 1246.2 ± 474.7*            |
|                   |           | Intratumoral  | 101.4 ± 25.5   | 151.0 ± 52.9               | 165.4 ± 38.9   | 222.9 ± 94.0               |
| Tbet⁺ T cells     | Tbet⁺(CD3 CD8⁺) | Stromal     | 230.1 ± 66.1   | 317.1 ± 65.2               | 621.9 ± 228.7  | 325.4 ± 93.1*              |
|                   |           | Intratumoral  | 193.5 ± 64.1   | 429.7 ± 190.6              | 159.7 ± 19.9   | 212.6 ± 74.5               |
| Tbet⁺ Tregs       | CD8⁺FoxP3⁺Tbet⁺ | Stromal     | 223.8 ± 78.8   | 152.3 ± 20.6               | 299.6 ± 98.2   | 116.2 ± 37.7               |
|                   |           | Intratumoral  | 56.0 ± 17.9    | 105.2 ± 26.1               | 74.9 ± 32.1    | 46.1 ± 24.2                |
| FoxP3⁺Tbet⁺CD8⁺ T cells | CD8⁺FoxP3⁺Tbet⁺ | Stromal     | 26.1 ± 19.2    | 38.8 ± 20.1                | 25.0 ± 8.3     | 99.6 ± 22.7*               |
|                   |           | Intratumoral  | 10.3 ± 7.4     | 9.0 ± 5.2                  | 11.2 ± 5.3     | 7.0 ± 2.1                  |
| Proliferating Tbet⁺CD8⁺ T cells | CD8⁺Ki67⁺Tbet⁺ | Stromal     | 61.7 ± 36.5    | 38.8 ± 9.5                 | 58.7 ± 11.9    | 82.3 ± 25.5                |
|                   |           | Intratumoral  | 61.4 ± 19.2    | 85.5 ± 42.9                | 112.8 ± 24.7   | 18.3 ± 3.0                 |

Data are presented as the mean number of cells/mm² ± standard error of the mean; ⁺Tregs: regulatory T cells; *P = 0.01 - 0.05 as calculated by the Wilcoxon signed rank (paired) test.